Please expect a full write-up and a transaction alert email with additional details soon. The company is being considered for inclusion into the Best Ideas portfolio.
“Senate Finance Committee Chairman Ron Wyden and senior Finance Committee member Chuck Grassley made public their request for detailed pricing information on Gilead’s (GILD) Sovaldi, a Hepatitis C virus drug. Wyden and Grassley have asked Gilead Sciences for information about Sovaldi, a drug developed to treat and cure HCV, they disclosed, stating, “Given the impact Sovaldi’s cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug.” — source
Please select the image below to download the firm’s 16-page report.
Appendix – Gilead Sciences
Marketed Products
Image Source: Gilead
Pipeline
Image Source: Gilead